+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6052554
The diabetic neuropathic pain market was valued at USD 3.30 Billion in 2024, driven by the increasing prevalence of diabetes across the 8 major markets. The market is expected to grow at a CAGR of 7.72% during the forecast period of 2025-2034, with the values likely to reach USD 6.94 Billion by 2034 .

Diabetic Neuropathic Pain Market Overview

Diabetic neuropathic pain occurs as a result of nerve damage in an individual suffering from diabetes. The pain from diabetic neuropathy can range from tingling in the toes or minor discomfort to severe and sharp pain. The damage to the nerves, primarily in the legs and feet, is caused by the high blood sugar levels in the diabetic patient’s body. Around 20 million Americans are reported to suffer from diabetic neuropathic pain. The increasing prevalence of diabetes is a significant factor driving the demand for effective treatments for the condition. The market growth is also supported by the rising introduction of new medications for targeted pain relief such as serotonin and norepinephrine reuptake inhibitors (SNRIs), anticonvulsants, and topical treatments. Additionally, the growing awareness among patients about diabetic neuropathic pain and the rise in drug approvals by regulatory agencies are anticipated to fuel the market growth.

Diabetic Neuropathic Pain Market Growth Drivers

Increasing Prevalence of Diabetes Drives Market Growth

According to the IDF Diabetes Atlas, 1 in 8 adults, or roughly 783 million individuals are projected to be living with diabetes by 2045, due to factors such as rapid urbanization, a growing aging population, sedentary lifestyle patterns, and rising obesity rates. Diabetic neuropathy is considered the most common complication of diabetes mellitus. It affects around 50% of patients with type 1 and type 2 diabetes mellitus. Thus, the rising number of cases of diabetes is one of the primary drivers of the market for diabetic neuropathic pain, propelling the demand for effective treatment options and advanced pain management therapies.

Diabetic Neuropathic Pain Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Regulatory Approvals of Innovative Treatments to Affect the Market Landscape Significantly

In January 2024, Neuralace Medical, Inc., a startup medical technology company specializing in non-invasive chronic pain relief devices announced the US Food and Drug Administration (FDA) approval of its Axon Therapy, becoming the first-ever FDA-cleared non-invasive, magnetic peripheral nerve stimulation (mPNS) treatment for patients with painful diabetic neuropathy. The rise in regulatory approvals of such innovative, patient-centered, non-invasive solutions is expected to bolster the market growth in the forecast period.

Increased Clinical Research Poised to Augment Diabetic Neuropathic Pain Market Demand

In March 2024, researchers at the UT Southwestern Medical Center conducted a randomized control trial which showed that surgical nerve decompression, which is often used to treat carpal tunnel syndrome and sciatica, might be effective for patients with diabetic peripheral neuropathy. The research study indicated that nerve decompression surgery can release compressed nerves from the surrounding tissue, which can help in offering lasting pain relief to the affected individuals. The growth in such clinical studies to likely to augment the market demand.

Rising Adoption of Non-Opioid Pain Management to Elevate the Diabetic Neuropathic Pain Market Value

A major market trend is the growing preference for non-opioid pain management options such as non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and topical treatments. Moreover, the patients are also seeking alternative therapies, such as acupuncture, spinal cord stimulation, and transcutaneous electrical nerve stimulation (TENS), which is likely to impact the market dynamics positively.

Shift Towards Multimodal Pain Management to Boost Diabetic Neuropathic Pain Market Size

One of the significant market trends is the growing use of combination therapies for the effective management of diabetic neuropathic pain. The patients are increasingly prescribed different pharmacological treatments to improve pain relief and reduce side effects. In addition, non-pharmacological methods are also being integrated with traditional drug therapies to enhance clinical benefits.

Diabetic Neuropathic Pain Market Segmentation

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
  • Others

Market Breakup by Treatment

  • Drugs
  • Analgesics
  • NSAIDs
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
  • Radiotherapy
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by End User

  • Hospitals & Clinics
  • Specialty Centers
  • Homecare Settings
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • India
  • Japan

Diabetic Neuropathic Pain Market Share

The Peripheral Neuropathy Segment Based on Type Holds a Significant Market Share

The market segmentation by type includes peripheral neuropathy, autonomic neuropathy, proximal neuropathy, focal neuropathy, and others. Peripheral neuropathy ranks as the most common form of diabetic neuropathy. The condition impacts the peripheral nerves (usually legs and feet) and causes symptoms such as burning sensations, tingling, and sharp pain. The high demand for treatments for peripheral neuropathy, including medications such as anticonvulsants, antidepressants, and topical agents, is propelling the growth of the segment.

Diabetic Neuropathic Pain Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents one of the largest markets for diabetic neuropathic pain due to the high prevalence of diabetes and the strong presence of major pharmaceutical companies. The growing demand for innovative therapies in the region, including both pharmacological treatments and non-pharmacological options (such as neuromodulation devices) is driving market growth. Moreover, the rising patient awareness regarding early diagnosis and management of diabetic neuropathy is expected to elevate the market value in the country in the coming years.

Leading Players in the Diabetic Neuropathic Pain Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Pfizer, Inc

Pharmaceutical industry company Pfizer Inc., headquartered in New York, United States, has a prominent presence in the market and is known for its robust portfolio of medications for pain management and neurological disorders. Pfizer's LYRICA® CR (pregabalin) extended-release tablets CV is a once-daily FDA-cleared therapy indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

NeuroMetrix, Inc

NeuroMetrix, Inc., based in Massachusetts, United States, is a spinoff of the Harvard-MIT Division of Health Sciences and Technology. This commercial-stage neurotechnology company is engaged in developing and marketing products that detect, diagnose, and monitor peripheral nerve and spinal cord disorders including diabetic neuropathy.

GSK plc

GSK plc, a British multinational pharmaceutical and biotechnology company, is one of the leading players in the market. The company is known for its extensive research capabilities and a wide range of neurological and pain management products. GSK-3858279, an immunomodulatory monoclonal antibody that targets CCL17, is under clinical development for the treatment of diabetic neuropathic pain.

Johnson & Johnson

Johnson & Johnson, headquartered in New Brunswick, New Jersey, plays a significant role in the growth of the market. One of the key products of Johnson & Johnson Innovative Medicine is an oral analgesic NUCYNTA® ER (tapentadol) extended-release tablets for the management of diabetic neuropathy pain.

Other key players in the market include Lupin, Astellas Pharma, Eli Lilly and Company, Glenmark, Sun Pharmaceuticals Ltd, and Abbott.

Key Questions Answered in the Diabetic Neuropathic Pain Market Report

  • What was the diabetic neuropathic pain market value in 2024?
  • What is the diabetic neuropathic pain market forecast outlook for 2025-2034?
  • What are the regional markets covered in the report?
  • What is market segmentation based on the type?
  • What is the market breakup based on treatment?
  • What is the market breakup by the route of administration?
  • Who are the major end users in the market?
  • What are the major factors aiding the diabetic neuropathic pain market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • How do the prevalence and incidence of diabetes affect the market landscape?
  • What are the major diabetic neuropathic pain market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which disorder will dominate the market share?
  • Which treatment is expected to have a high market value in the coming years?
  • Which route of administration will experience the highest demand in the market segment?
  • Which end user is projected to contribute to the highest market growth?
  • Who are the key players involved in the diabetic neuropathic pain market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetic Neuropathic Pain Market Overview - 8 Major Markets
3.1 Diabetic Neuropathic Pain Market Historical Value (2018-2024)
3.2 Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Diabetic Neuropathic Pain Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Diabetic Neuropathic Pain Market - Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 United States
7.1.1.2 United Kingdom
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 United States
7.1.2.2 United Kingdom
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 United States
7.1.3.2 United Kingdom
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Diabetic Neuropathic Pain Market Landscape - 8 Major Markets
8.1 Diabetic Neuropathic Pain Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Diabetic Neuropathic Pain Market: Product Landscape
8.2.1 Analysis by Treatment
8.2.2 Analysis by Route of Administration
9 Diabetic Neuropathic Pain Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Diabetic Neuropathic Pain Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Diabetic Neuropathic Pain Market Segmentation (218-2034) - 8 Major Markets
12.1 Diabetic Neuropathic Pain Market (2018-2034) by Type
12.1.1 Market Overview
12.1.2 Peripheral Neuropathy
12.1.3 Autonomic Neuropathy
12.1.4 Proximal Neuropathy
12.1.5 Focal Neuropathy
12.1.6 Others
12.2 Diabetic Neuropathic Pain Market (2018-2034) by Treatment
12.2.1 Market Overview
12.2.2 Drugs
12.2.2.1 Analgesics
12.2.2.2 NSAIDs
12.2.2.3 Antidepressants
12.2.2.4 Anticonvulsant Drugs
12.2.2.5 Others
12.2.3 Radiotherapy
12.2.4 Others
12.3 Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
12.3.1 Market Overview
12.3.2 Oral
12.3.3 Parenteral
12.3.4 Others
12.4 Diabetic Neuropathic Pain Market (2018-2034) by End User
12.4.1 Market Overview
12.4.2 Hospitals & Clinics
12.4.3 Specialty Centers
12.4.4 Homecare Settings
12.4.5 Others
12.5 Diabetic Neuropathic Pain Market (2018-2034) by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
12.5.5 India
13 United States Diabetic Neuropathic Pain Market (218-2034)
13.1 United States Diabetic Neuropathic Pain Market Historical Value (2018-2024)
13.2 United States Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
13.3 United States Diabetic Neuropathic Pain Market (2018-2034) by Type
13.3.1 Market Overview
13.3.2 Peripheral Neuropathy
13.3.3 Autonomic Neuropathy
13.3.4 Proximal Neuropathy
13.3.5 Focal Neuropathy
13.3.6 Others
13.4 United States Diabetic Neuropathic Pain Market (2018-2034) by Treatment
13.4.1 Market Overview
13.4.2 Drugs
13.4.2.1 Analgesics
13.4.2.2 NSAIDs
13.4.2.3 Antidepressants
13.4.2.4 Anticonvulsant Drugs
13.4.2.5 Others
13.4.3 Radiotherapy
13.4.4 Others
13.5 United States Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Parenteral
13.5.4 Others
13.6 United States Diabetic Neuropathic Pain Market (2018-2034) by End User
13.6.1 Market Overview
13.6.2 Hospitals & Clinics
13.6.3 Specialty Centers
13.6.4 Homecare Settings
13.6.5 Others
14 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (218-2034)
14.1 EU-4 and United Kingdom Diabetic Neuropathic Pain Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Type
14.3.1 Market Overview
14.3.2 Peripheral Neuropathy
14.3.3 Autonomic Neuropathy
14.3.4 Proximal Neuropathy
14.3.5 Focal Neuropathy
14.3.6 Others
14.4 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Treatment
14.4.1 Market Overview
14.4.2 Drugs
14.4.2.1 Analgesics
14.4.2.2 NSAIDs
14.4.2.3 Antidepressants
14.4.2.4 Anticonvulsant Drugs
14.4.2.5 Others
14.4.3 Radiotherapy
14.4.4 Others
14.5 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
14.5.1 Market Overview
14.5.2 Oral
14.5.3 Parenteral
14.5.4 Others
14.6 EU-4 and United Kingdom Diabetic Neuropathic Pain Market (2018-2034) by End User
14.6.1 Market Overview
14.6.2 Hospitals & Clinics
14.6.3 Specialty Centers
14.6.4 Homecare Settings
14.6.5 Others
15 Japan Diabetic Neuropathic Pain Market
15.1 Japan Diabetic Neuropathic Pain Market Historical Value (2018-2024)
15.2 Japan Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
15.3 Japan Diabetic Neuropathic Pain Market (2018-2034) by Type
15.3.1 Market Overview
15.3.2 Peripheral Neuropathy
15.3.3 Autonomic Neuropathy
15.3.4 Proximal Neuropathy
15.3.5 Focal Neuropathy
15.3.6 Others
15.4 Japan Diabetic Neuropathic Pain Market (2018-2034) by Treatment
15.4.1 Market Overview
15.4.2 Drugs
15.4.2.1 Analgesics
15.4.2.2 NSAIDs
15.4.2.3 Antidepressants
15.4.2.4 Anticonvulsant Drugs
15.4.2.5 Others
15.4.3 Radiotherapy
15.4.4 Others
15.5 Japan Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
15.5.1 Market Overview
15.5.2 Oral
15.5.3 Parenteral
15.5.4 Others
15.6 Japan Diabetic Neuropathic Pain Market (2018-2034) by End User
15.6.1 Market Overview
15.6.2 Hospitals & Clinics
15.6.3 Specialty Centers
15.6.4 Homecare Settings
15.6.5 Others
16 India Diabetic Neuropathic Pain Market
16.1 India Diabetic Neuropathic Pain Market Historical Value (2018-2024)
16.2 India Diabetic Neuropathic Pain Market Forecast Value (2025-2034)
16.3 India Diabetic Neuropathic Pain Market (2018-2034) by Type
16.3.1 Market Overview
16.3.2 Peripheral Neuropathy
16.3.3 Autonomic Neuropathy
16.3.4 Proximal Neuropathy
16.3.5 Focal Neuropathy
16.3.6 Others
16.4 India Diabetic Neuropathic Pain Market (2018-2034) by Treatment
16.4.1 Market Overview
16.4.2 Drugs
16.4.2.1 Analgesics
16.4.2.2 NSAIDs
16.4.2.3 Antidepressants
16.4.2.4 Anticonvulsant Drugs
16.4.2.5 Others
16.4.3 Radiotherapy
16.4.4 Others
16.5 India Diabetic Neuropathic Pain Market (2018-2034) by Route of Administration
16.5.1 Market Overview
16.5.2 Oral
16.5.3 Parenteral
16.5.4 Others
16.6 India Diabetic Neuropathic Pain Market (2018-2034) by End User
16.6.1 Market Overview
16.6.2 Hospitals & Clinics
16.6.3 Specialty Centers
16.6.4 Homecare Settings
16.6.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 Japan PMDA
17.5 India CDSCO
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grants Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Application
20.5 Analysis by Funding Institute
20.6 Analysis by NIH Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Treatment Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Treatment Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share Analysis, By Region (Top 5 Companies)
23.2 Pfizer , Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Companies News and Developments
23.2.5 Certifications
23.3 NeuroMetrix, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Companies News and Developments
23.3.5 Certifications
23.4 GSK plc
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Companies News and Developments
23.4.5 Certifications
23.5 Johnson & Johnson
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Companies News and Developments
23.5.5 Certifications
23.6 Lupin
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Companies News and Developments
23.6.5 Certifications
23.7 Astellas Pharma
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Companies News and Developments
23.7.5 Certifications
23.8 Eli Lily and Company
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Companies News and Developments
23.8.5 Certifications
23.9 Glenmark
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Companies News and Developments
23.9.5 Certifications
23.10 Sun Pharmaceuticals Ltd
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Companies News and Developments
23.10.5 Certifications
23.11 Abbott
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Companies News and Developments
23.11.5 Certifications
24 Diabetic Neuropathic Pain Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)26 Payment Methods (Additional Insight)

Companies Mentioned

  • Pfizer, Inc.
  • NeuroMetrix, Inc.
  • GSK plc
  • Johnson & Johnson

Table Information